1. Clarke IN, Lambden PR. The molecular biology of caliciviruses. J GEN VIROL. 1997;78(Pt 2):(2):291–301.
2. Di Martino B, Di Rocco C, Ceci C, Marsilio F. Characterization of a strain of feline calicivirus isolated from a dog faecal sample. VET MICROBIOL. 2009;139(1–2):52–7.
3. Martella V, Pratelli A, Gentile M, Buonavoglia D, Decaro N, Fiorente P, Buonavoglia C. Analysis of the capsid protein gene of a feline-like calicivirus isolated from a dog. VET MICROBIOL. 2002;85(4):315–22.
4. Battilani M, Vaccari F, Carelle MS, Morandi F, Benazzi C, Kipar A, Dondi F, Scagliarini A. Virulent feline calicivirus disease in a shelter in Italy: a case description. RES VET SCI. 2013;95(1):283–90.
5. Dedication. In: Consultations in Feline Internal Medicine (Fifth Edition). Edited by August JR. Saint Louis: W.B. Saunders; 2006: v.
6. Sykes JE. Pediatric feline upper respiratory disease. Vet Clin North Am Small Anim Pract. 2014;44(2):331–42.
7. Hurley KF, Sykes JE. Update on feline calicivirus: new trends. Vet Clin North Am Small Anim Pract. 2003;33(4):759–72.
8. Cohn LA. Feline respiratory disease complex. Vet Clin North Am Small Anim Pract. 2011;41(6):1273–89.
9. Willi B, Spiri AM, Meli ML, Samman A, Hoffmann K, Sydler T, Cattori V, Graf F, Diserens KA, Padrutt I, et al. Molecular characterization and virus neutralization patterns of severe, non-epizootic forms of feline calicivirus infections resembling virulent systemic disease in cats in Switzerland and in Liechtenstein. VET MICROBIOL. 2016;182:202–12.
10. Coyne KP, Gaskell RM, Dawson S, Porter CJ, Radford AD. Evolutionary mechanisms of persistence and diversification of a calicivirus within endemically infected natural host populations. J VIROL. 2007;81(4):1961–71.
11. Radford AD, Coyne KP, Dawson S, Porter CJ, Gaskell RM. Feline calicivirus. VET RES. 2007;38(2):319–35.
12. Smith AW, Iversen PL, O'Hanley PD, Skilling DE, Christensen JR, Weaver SS, Longley K, Stone MA, Poet SE, Matson DO. Virus-specific antiviral treatment for controlling severe and fatal outbreaks of feline calicivirus infection. AM J VET RES. 2008;69(1):23–32.
13. Wu H, Zhang X, Liu C, Liu D, Liu J, Tian J, Qu L. Antiviral effect of lithium chloride on feline calicivirus in vitro. ARCH VIROL. 2015;160(12):2935–43.
14. Wu H, Liu Y, Zu S, Sun X, Liu C, Liu D, Zhang X, Tian J, Qu L. In vitro antiviral effect of germacrone on feline calicivirus. ARCH VIROL. 2016;161(6):1559–67.
15. McDonagh P, Sheehy PA, Fawcett A, Norris JM. Antiviral effect of mefloquine on feline calicivirus in vitro. VET MICROBIOL. 2015;176(3–4):370–7.
16. Horie M, Ogawa H, Yoshida Y, Yamada K, Hara A, Ozawa K, Matsuda S, Mizota C, Tani M, Yamamoto Y, et al. Inactivation and morphological changes of avian influenza virus by copper ions. ARCH VIROL. 2008;153(8):1467–72.
17. Shahabadi N, Abbasi AR, Moshtkob A, Shiri F. DNA-binding studies of a new Cu(II) complex containing reverse transcriptase inhibitor and anti-HIV drug zalcitabine. Journal of Coordination ChemistryJournal of Coordination Chemistry. 2019;72(12):1957–72.
18. Sucipto TH, Churrotin S, Setyawati H, Kotaki T, Martak F, Soegijanto S. ANTIVIRAL ACTIVITY OF COPPER(II) CHLORIDE DIHYDRATE AGAINST DENGUE VIRUS TYPE-2 IN VERO CELL. Indonesian Journal of Tropical Infectious Disease. 2017;6(4):84–7.
19. Jopp M, Becker J, Becker S, Miska A, Gandin V, Marzano C, Schindler S. Anticancer activity of a series of copper(II) complexes with tripodal ligands. EUR J MED CHEM. 2017;132:274–81.
20. Zhao Y, Chen X, Ying Y, Wang K, Dong H, Gao C, Yang S, Hu G. Isolation and phylogenetic analysis of three feline calicivirus strains from domestic cats in Jilin Province, China. ARCH VIROL 2017, 162(9).
21. Sagripanti JL, Routson LB, Bonifacino AC, Lytle CD. Mechanism of copper-mediated inactivation of herpes simplex virus. Antimicrob Agents Chemother. 1997;41(4):812–7.
22. Betanzos-Cabrera G, Rez FJR, Oz JLM, Barrè´¸n BL, Maldonado R. Inactivation of HSV-2 by ascorbate-Cu(II) and its protecting evaluation in CF-1 mice against encephalitis. J VIROL METHODS. 2004;120(2):161–5.
23. Sagripanti JL, Routson LB, Bonifacino AC, Lytle CD. Mechanism of copper-mediated inactivation of herpes simplex virus. 1997, 41(4):812.
24. Wen-Jie G, Si-Si Y, Ning C, Juan H, Jing G, Qiu-Yun C. ROS-mediated autophagy was involved in cancer cell death induced by novel copper(II) complex. 2010, 62(5):577–582.
25. Strauch BM, Niemand RK, Winkelbeiner NL, Hartwig A. Comparison between micro- and nanosized copper oxide and water soluble copper chloride: interrelationship between intracellular copper concentrations, oxidative stress and DNA damage response in human lung cells. PART FIBRE TOXICOL. 2017;14(1):17–28.
26. Yadav B, Wennerberg K, Aittokallio T, Tang J. Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model. Computational Structural Biotechnology Journal. 2015;13(C):504–13.
27. Kim Y, Chang K. Fexaramine as an entry blocker for feline caliciviruses. ANTIVIR RES. 2018;152:76–83.
28. Aboubakr HA, Nauertz A, Luong NT, Agrawal S, El-Sohaimy SAA, Youssef MM, Goyal SM. In Vitro Antiviral Activity of Clove and Ginger Aqueous Extracts against Feline Calicivirus, a Surrogate for Human Norovirus. J FOOD PROTECT. 2016;79(6):1001–12.
29. Smith MA, Easton M, Everett P, Lewis G, Payne M, Riveros-Moreno V, Allen G. Specific cleavage of immunoglobulin G by copper ions. International Journal of Peptide Protein Research. 2010;48(1):48–55.
30. Cui Z, Li D, Yi S, Guo Y, Dong G, Niu J, Zhao H, Zhang Y, Zhang S, Cao L, et al: Equine immunoglobulin F(ab') 2 fragments protect cats against feline calicivirus infection. INT IMMUNOPHARMACOL 2019, 75.
31. Jasenosky LD, Cadena C, Mire CE, Borisevich V, Haridas V, Ranjbar S, Nambu A, Bavari S, Soloveva V, Sadukhan S, et al: The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus. iScience 2019, 19:1279–1290.
32. Ianevski A, He L, Aittokallio T, Tang J. SynergyFinder: a web application for analyzing drug combination dose-response matrix data. Bioinformatics. 2017;33(15):2413–5.